MIMEDX Group, Inc. announced the launch of EPIEFFECT??, the Company's latest addition to its portfolio of AWC solutions. EPIEFFECT expands the Company's core AWC offering for clinicians treating acute and chronic, hard-to-heal wounds such as diabetic foot ulcers ("DFUs") and venous leg ulcers ("VLUs"), among other common conditions. EPIEFFECT offers a thick, tri-layer configuration that is suitable for securing the graft in place with sutures.

In addition, its product attributes and handling characteristics make it a preferable treatment option for deep or tunneling wounds. EPIEFFECT is a lyophilized human placental-based allograft consisting of amnion and chorion membranes, while also retaining the intermediate layer. EPIEFFECT is intended for use as a barrier, to provide a protective environment in acute and chronic wounds; the tissue provides a biocompatible human extracellular matrix (?ECM?) and contains more than 300 regulatory proteins.

EPIEFFECT is available in a variety of size options ranging from 6 cm2 to 49 cm2. Additionally, like EPIFIX® and EPICORD®, EPIEFFECT is listed on the Medicare Part B Average Sales Price File, effective October 1, 2023.